Indolent B-cell non-Hodgkin lymphoma

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This phase 2 trial is testing whether the drug loncastuximab tesirine (Lonca) can help patients with large B-cell lymphoma who had only a partial response after CAR T-cell therapy achieve a complete remission. About 30 adults will receive Lonca as a consolidation treatment. The s…

This early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …

This study is testing whether a combination of two drugs, epcoritamab and rituximab, can effectively treat follicular lymphoma in people who have not had any prior treatment. The trial will enroll about 100 adults with CD20-positive follicular lymphoma. The goal is to see how man…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This study compares a reduced radiation dose (3 treatments) against the standard 12 treatments for people with indolent (slow-growing) non-Hodgkin lymphoma. The goal is to see if the shorter course is safer and still works well at controlling the cancer. About 112 adults with cer…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participant…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…

This study tests whether the drug pacritinib is safe and effective for adults with Waldenström macroglobulinemia, a rare blood cancer, when previous treatments have stopped working. About 30 participants will receive pacritinib and be monitored for tumor shrinkage and side effect…

This early-stage trial tests a new therapy made from cord blood immune cells (CAR NK cells) designed to target and kill B-cell lymphoma cells. It is for patients whose cancer has not responded to or has returned after standard treatments. The study will check safety and how well …

This early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those wh…

This study tests a personalized program combining exercise and nutrition advice to help reduce fatigue in people with indolent (slow-growing) lymphomas, such as chronic lymphocytic leukemia and follicular lymphoma. Participants receive an individualized exercise plan and dietary …

This study follows 150 adults aged 70 and older with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to track well-being from diagnosis through one year after therapy starts. The goal is to identify whi…

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…

This study looks at a rare event where an aggressive lymphoma (DLBCL) comes back as a slow-growing (indolent) lymphoma. Researchers will review medical records of 50 adults to understand how often this happens, what treatments are used, and how well patients do. The goal is to ga…

This study aims to collect tissue samples and medical information from up to 2,750 people with chronic lymphocytic leukemia (CLL) or related conditions. Researchers hope to learn more about what causes CLL and how it behaves. Participants will not receive any new treatment; the g…

This study looks at how short-term and long-term exercise affects the immune system in people with slow-growing blood cancers like chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL). Researchers at Mayo Clinic will have 70 participants undergo a 12-week ex…